FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247863341> ?p ?o ?g. }

• W4247863341 endingPage "ii23" @default.
• W4247863341 startingPage "ii23" @default.
• W4247863341 abstract "BACKGROUND: Molecular biomarkers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q codeletion, mutations and (consequently) loss of expression of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation, improve prognostication and may even guide treatment decisions in patients with anaplastic gliomas. Illumina Infinium HumanMethylation450 BeadChip arrays (HM450) allow the determination of large-scale methylation profiles and genome-wide DNA copy number changes, enabling molecular subgrouping of tumors. In addition, algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion and MGMT promoter methylation using this assay. METHODS: In the biomarker cohort of the NOA-04 trial, the diagnostic and prognostic performance of these molecular markers using single tests, HM450 data and HM450-based algorithms has been investigated to propose biological subgroups, which reflect outcomes and potentially influence treatment decisions. RESULTS: Loss of ATRX expression was detected in 45% of anaplastic astrocytomas (AA), 27% of anaplastic oligoastrocytomas (AOA) and 10% of anaplastic oligodendrogliomas (AO). It was mostly restricted to IDH mutant tumors and almost mutually exclusive with 1p/19q co-deletion. In tumors with IDH1 mutation, MGMT promoter methylation was associated with prolonged progression-free survival (PFS) with chemotherapy or radiotherapy (RT), and thus prognostic. In tumors without IDH1 mutation, MGMT promoter methylation was associated with increased PFS in patients treated with chemotherapy, too, but not in those who received RT alone as the first-line treatment, and is thus chemotherapy-predictive. Comparisons of single assays and HM450-based algorithms revealed a high concordance for IDH and 1p/19q status. The HM450-derived MGMT-STP27 model to calculate MGMT promoter methylation probability revealed this aberration in a significantly higher fraction of cases as conventional methylation-specific PCR, with 87/91 G-CIMP-positive tumors predicted as MGMT promoter-methylated. CONCLUSIONS: ATRX loss is a hallmark and favorable prognosticator of astrocytic tumors allowing a better definition of the clinically and morphologically mixed group of AOA. MGMT promoter methylation is a predictive biomarker for benefit from alkylating agent chemotherapy in patients with IDH1-wildtype, but not IDH1-mutant malignant gliomas of WHO grades III/IV. Combined IDH1/ MGMT assessment may help to individualize clinical decision making in neurooncology. G-CIMP and 1p/19q codeletion are reliably detectable by HM450 analysis and associated with prognosis in the NOA-04 trial. HM450 arrays allowed clustering of anaplastic gliomas into relevant subgroups." @default.
• W4247863341 created "2022-05-12" @default.
• W4247863341 creator A5014129073 @default.
• W4247863341 creator A5017177249 @default.
• W4247863341 creator A5021213250 @default.
• W4247863341 creator A5022459054 @default.
• W4247863341 creator A5027224009 @default.
• W4247863341 creator A5039647180 @default.
• W4247863341 creator A5039985608 @default.
• W4247863341 creator A5052657395 @default.
• W4247863341 creator A5074018145 @default.
• W4247863341 creator A5080723968 @default.
• W4247863341 date "2014-09-01" @default.
• W4247863341 modified "2023-09-26" @default.
• W4247863341 title "O10.01 * PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL" @default.
• W4247863341 doi "https://doi.org/10.1093/neuonc/nou174.82" @default.
• W4247863341 hasPublicationYear "2014" @default.
• W4247863341 type Work @default.
• W4247863341 citedByCount "2" @default.
• W4247863341 countsByYear W42478633412015 @default.
• W4247863341 crossrefType "journal-article" @default.
• W4247863341 hasAuthorship W4247863341A5014129073 @default.
• W4247863341 hasAuthorship W4247863341A5017177249 @default.
• W4247863341 hasAuthorship W4247863341A5021213250 @default.
• W4247863341 hasAuthorship W4247863341A5022459054 @default.
• W4247863341 hasAuthorship W4247863341A5027224009 @default.
• W4247863341 hasAuthorship W4247863341A5039647180 @default.
• W4247863341 hasAuthorship W4247863341A5039985608 @default.
• W4247863341 hasAuthorship W4247863341A5052657395 @default.
• W4247863341 hasAuthorship W4247863341A5074018145 @default.
• W4247863341 hasAuthorship W4247863341A5080723968 @default.
• W4247863341 hasBestOaLocation W42478633411 @default.
• W4247863341 hasConcept C104317684 @default.
• W4247863341 hasConcept C126322002 @default.
• W4247863341 hasConcept C127848430 @default.
• W4247863341 hasConcept C143998085 @default.
• W4247863341 hasConcept C150194340 @default.
• W4247863341 hasConcept C181199279 @default.
• W4247863341 hasConcept C190727270 @default.
• W4247863341 hasConcept C2776059313 @default.
• W4247863341 hasConcept C2776689207 @default.
• W4247863341 hasConcept C2777150147 @default.
• W4247863341 hasConcept C2779527866 @default.
• W4247863341 hasConcept C2781197716 @default.
• W4247863341 hasConcept C33288867 @default.
• W4247863341 hasConcept C501734568 @default.
• W4247863341 hasConcept C502942594 @default.
• W4247863341 hasConcept C54355233 @default.
• W4247863341 hasConcept C55493867 @default.
• W4247863341 hasConcept C71924100 @default.
• W4247863341 hasConcept C86803240 @default.
• W4247863341 hasConcept C91965660 @default.
• W4247863341 hasConceptScore W4247863341C104317684 @default.
• W4247863341 hasConceptScore W4247863341C126322002 @default.
• W4247863341 hasConceptScore W4247863341C127848430 @default.
• W4247863341 hasConceptScore W4247863341C143998085 @default.
• W4247863341 hasConceptScore W4247863341C150194340 @default.
• W4247863341 hasConceptScore W4247863341C181199279 @default.
• W4247863341 hasConceptScore W4247863341C190727270 @default.
• W4247863341 hasConceptScore W4247863341C2776059313 @default.
• W4247863341 hasConceptScore W4247863341C2776689207 @default.
• W4247863341 hasConceptScore W4247863341C2777150147 @default.
• W4247863341 hasConceptScore W4247863341C2779527866 @default.
• W4247863341 hasConceptScore W4247863341C2781197716 @default.
• W4247863341 hasConceptScore W4247863341C33288867 @default.
• W4247863341 hasConceptScore W4247863341C501734568 @default.
• W4247863341 hasConceptScore W4247863341C502942594 @default.
• W4247863341 hasConceptScore W4247863341C54355233 @default.
• W4247863341 hasConceptScore W4247863341C55493867 @default.
• W4247863341 hasConceptScore W4247863341C71924100 @default.
• W4247863341 hasConceptScore W4247863341C86803240 @default.
• W4247863341 hasConceptScore W4247863341C91965660 @default.
• W4247863341 hasIssue "suppl 2" @default.
• W4247863341 hasLocation W42478633411 @default.
• W4247863341 hasLocation W42478633412 @default.
• W4247863341 hasOpenAccess W4247863341 @default.
• W4247863341 hasPrimaryLocation W42478633411 @default.
• W4247863341 hasRelatedWork W1794341117 @default.
• W4247863341 hasRelatedWork W1979801327 @default.
• W4247863341 hasRelatedWork W2130377532 @default.
• W4247863341 hasRelatedWork W2151478922 @default.
• W4247863341 hasRelatedWork W2185182801 @default.
• W4247863341 hasRelatedWork W2332478159 @default.
• W4247863341 hasRelatedWork W4200606830 @default.
• W4247863341 hasRelatedWork W4283447686 @default.
• W4247863341 hasRelatedWork W4306404899 @default.
• W4247863341 hasRelatedWork W4308977718 @default.
• W4247863341 hasVolume "16" @default.
• W4247863341 isParatext "false" @default.
• W4247863341 isRetracted "false" @default.
• W4247863341 workType "article" @default.